Non-persistent effect of short-term bisphosphonate treatment in preventing fractures after liver transplantation

Bodingbauer, Martin; Pakrah, B.; Kristo, Ivan; Marschalek, Julian; Burghuber, Christopher; Györi, Georg; Kainz, Alexander; Rasoul‐Rockenschaub, Susanne; Klaushofer, Klaus; Muehlbacher, Ferdinand; Oberbauer, Rainer

doi:10.1111/j.1432-2277.2009.00918.x

Cited by 5 publications

(3 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems unlikely that zoledronic acid will be able to be used annually in liver transplantation, as the ability of zoledronic acid to prevent bone fractures after liver transplantation is lost within 12 months of treatment. 21 Thus, three ‘late’ asymptomatic fractures occurred in a group of 28 subjects who had had liver transplants, and been treated with zoledronic acid. 21…”

Section: Glucocorticoid-induced Secondary Osteoporosismentioning

confidence: 99%

“…21 Thus, three ‘late’ asymptomatic fractures occurred in a group of 28 subjects who had had liver transplants, and been treated with zoledronic acid. 21…”

Section: Glucocorticoid-induced Secondary Osteoporosismentioning

confidence: 99%

“…It seems unlikely that zoledronic acid will be able to be used once-yearly in the bone loss associated with liver transplantation, as the ability of zoledronic acid to prevent bone fractures after liver transplantation is lost within 12 months of treatment. 21…”

Section: Commentarymentioning

confidence: 99%

See 2 more Smart Citations

Zoledronic Acid Once-yearly: What Role in the Prevention of Non-vertebral Osteoporotic Fractures?

Doggrell

2010

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Osteoporosis is the most common bone disease. Low levels of oestrogens or testosterone are risk factors for primary osteoporosis. The most common cause of secondary osteoporosis is glucocorticoid treatment, but there are many other secondary causes of osteoporosis. Osteoporosis can be secondary to anti-oestrogen treatment for hormone-sensitive breast cancer and to androgen-deprivation therapy for prostate cancer. Zoledronic acid is the most potent bisphosphonate at inhibiting bone resorption. In osteoporosis, zoledronic acid increases bone mineral density for at least a year after a single intravenous administration. The efficacy and safety of extended release (once-yearly) zoledronic acid in the treatment of osteoporosis is reviewed.

show abstract

Section: Glucocorticoid-induced Secondary Osteoporosismentioning

confidence: 99%

“…21 Thus, three ‘late’ asymptomatic fractures occurred in a group of 28 subjects who had had liver transplants, and been treated with zoledronic acid. 21…”

Section: Glucocorticoid-induced Secondary Osteoporosismentioning

confidence: 99%